Defunct Company
Total Trials
7
As Lead Sponsor
As Collaborator
0
Total Enrollment
128
NCT00988195
Study of Pegylated Human Recombinant Arginase for Liver Cancer
Phase: Phase 1
Role: Lead Sponsor
Start: May 31, 2008
Completion: Aug 31, 2009
NCT01092091
Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)
Phase: Phase 1/2
Start: Mar 31, 2010
Completion: Feb 29, 2012
NCT01551628
A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma
Start: Apr 30, 2012
Completion: May 31, 2013
NCT02089633
Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC
Phase: Phase 2
Start: Apr 30, 2014
Completion: Oct 31, 2016
NCT02089763
Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer
Completion: Mar 31, 2017
NCT02285101
Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors
Start: Nov 30, 2014
Completion: Feb 28, 2019
NCT02899286
Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Start: Sep 30, 2016
Completion: Mar 31, 2020